Bristol Myers Squibb highlights oncology pipeline, shares tracked against pharma peers

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 07:39.

Bristol Myers Squibb (US0897961004) remains a closely watched name on the NYSE as investors weigh its oncology pipeline against mature revenue drivers like Eliquis and Opdivo. Large-cap peers Merck and Pfizer provide the main valuation reference points for the stock, according to recent analyst commentary.Reuters analysis on large-cap pharma positioning

What analysts emphasize now

Research houses continue to highlight Bristol Myers Squibb’s late-stage portfolio in oncology and immunology, including assets such as the CELMoD class and next-generation checkpoint inhibitors. Several brokers see the company as a value play within U.S. big pharma, with focus on cash generation and capital returns.Morningstar profile on Bristol Myers Squibb

Consensus data compiled by independent platforms shows a mix of Buy and Hold ratings for Bristol Myers Squibb compared with generally higher growth expectations for Merck and AstraZeneca, reflecting different exposures to oncology ramps and patent expiries.MarketScreener analyst consensus overview

Positioning in the pharma peer group

On Wall Street Bristol Myers Squibb trades alongside S&P 500 healthcare constituents such as Johnson & Johnson and AbbVie, where investors compare dividend yield, pipeline depth and exposure to U.S. pricing dynamics. The company’s scale keeps it firmly in the large-cap biopharma universe on the NYSE.Financial Times healthcare sector overview

Sector watchers note that oncology, cardiovascular and immunology remain the three pillars of Bristol Myers Squibb’s strategy, with business development and partnerships used to complement internal research and development in these core areas.Bristol Myers Squibb annual reporting

How Bristol Myers Squibb earns money

Bristol Myers Squibb generates revenue primarily from prescription medicines in oncology, hematology, cardiovascular and immunology, with products such as Opdivo for cancer and Eliquis for stroke prevention representing key contributors to group sales.

Where the stock trades today

The Bristol Myers Squibb shares (US0897961004) most recently traded on the NYSE at around 54.70 US dollars per share, based on the closing levels of the latest session available from U.S. exchange data.

This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument. Investors should conduct their own research or consult a professional advisor before making investment decisions.